A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.

BACKGROUND: Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in phase 3 studies. OBJECTIVE: To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiologic chara...

Descripción completa

Detalles Bibliográficos
Autores: Ortiz Salvador JM, Saneleuterio Temporal M, Magdaleno Tapial J, Manel VP, Conrad PM, Sahuquillo Torralba A, Mateu-Puchades, Almudena, Pitarch-Bort, Gerard, Mari-Ruiz, Juan-Ignacio, Mataix Díaz J, Montesinos Villaescusa E, Miralles-Botella, Julia, Garcia-Fernandez, Laura, Martorell Calatayud A, Belinchon, I., Sánchez Carazo JL, Pérez Ferriols A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p3341
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/3341
Access Level:acceso abierto
Palabra clave:IL-17
biologic therapy
psoriasis
secukinumab
id ES_e4682c3a154c96ea96ba13333eb3efcd
oai_identifier_str oai:fisabio.fundanetsuite.com:p3341
network_acronym_str ES
network_name_str España
repository_id_str
spelling A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.Ortiz Salvador JMSaneleuterio Temporal MMagdaleno Tapial JManel VPConrad PMSahuquillo Torralba AMateu-Puchades, AlmudenaPitarch-Bort, GerardMari-Ruiz, Juan-IgnacioMataix Díaz JMontesinos Villaescusa EMiralles-Botella, JuliaGarcia-Fernandez, LauraMartorell Calatayud ABelinchon, I.Sánchez Carazo JLPérez Ferriols AIL-17biologic therapypsoriasissecukinumabBACKGROUND: Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in phase 3 studies. OBJECTIVE: To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiologic characteristics of patients treated with secukinumab in clinical settings. METHODS: In this multicenter prospective observational study, we recruited adult patients with moderate-to-severe plaque psoriasis from 12 hospitals in Spain during January-December 2016. These patients were treated with secukinumab and prospectively followed at 12-week intervals for 52 weeks. RESULTS: In total, 158 patients were recruited to the study. A Psoriasis Area and Severity Index (PASI) score improvement =75% over baseline (PASI-75) was achieved by 57%, 83.5%, 89%, and 78.5% of patients at weeks 4, 12, 24, and 52, respectively. PASI-90 was achieved in 27.8%, 62%, 64.6%, and 63.2% of patients at weeks 4, 12, 24, and 52, respectively; PASI-75 and PASI-90 responders were significantly more common among patients with a body mass index <30 kg/cm(2) and patients without previous biologic therapy failures. LIMITATIONS: Observational study. Time from onset of psoriasis was not evaluated. CONCLUSION: Secukinumab is a safe treatment with effectiveness rates similar to those found in its phase 3 studies. These rates endure up to a year from start of treatment.MOSBY-ELSEVIER2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/3341JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGYISSN: 01909622ISSNe: 10976787reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p33412026-06-11T12:45:17Z
dc.title.none.fl_str_mv A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
title A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
spellingShingle A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
Ortiz Salvador JM
IL-17
biologic therapy
psoriasis
secukinumab
title_short A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
title_full A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
title_fullStr A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
title_full_unstemmed A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
title_sort A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
dc.creator.none.fl_str_mv Ortiz Salvador JM
Saneleuterio Temporal M
Magdaleno Tapial J
Manel VP
Conrad PM
Sahuquillo Torralba A
Mateu-Puchades, Almudena
Pitarch-Bort, Gerard
Mari-Ruiz, Juan-Ignacio
Mataix Díaz J
Montesinos Villaescusa E
Miralles-Botella, Julia
Garcia-Fernandez, Laura
Martorell Calatayud A
Belinchon, I.
Sánchez Carazo JL
Pérez Ferriols A
author Ortiz Salvador JM
author_facet Ortiz Salvador JM
Saneleuterio Temporal M
Magdaleno Tapial J
Manel VP
Conrad PM
Sahuquillo Torralba A
Mateu-Puchades, Almudena
Pitarch-Bort, Gerard
Mari-Ruiz, Juan-Ignacio
Mataix Díaz J
Montesinos Villaescusa E
Miralles-Botella, Julia
Garcia-Fernandez, Laura
Martorell Calatayud A
Belinchon, I.
Sánchez Carazo JL
Pérez Ferriols A
author_role author
author2 Saneleuterio Temporal M
Magdaleno Tapial J
Manel VP
Conrad PM
Sahuquillo Torralba A
Mateu-Puchades, Almudena
Pitarch-Bort, Gerard
Mari-Ruiz, Juan-Ignacio
Mataix Díaz J
Montesinos Villaescusa E
Miralles-Botella, Julia
Garcia-Fernandez, Laura
Martorell Calatayud A
Belinchon, I.
Sánchez Carazo JL
Pérez Ferriols A
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv IL-17
biologic therapy
psoriasis
secukinumab
topic IL-17
biologic therapy
psoriasis
secukinumab
description BACKGROUND: Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in phase 3 studies. OBJECTIVE: To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiologic characteristics of patients treated with secukinumab in clinical settings. METHODS: In this multicenter prospective observational study, we recruited adult patients with moderate-to-severe plaque psoriasis from 12 hospitals in Spain during January-December 2016. These patients were treated with secukinumab and prospectively followed at 12-week intervals for 52 weeks. RESULTS: In total, 158 patients were recruited to the study. A Psoriasis Area and Severity Index (PASI) score improvement =75% over baseline (PASI-75) was achieved by 57%, 83.5%, 89%, and 78.5% of patients at weeks 4, 12, 24, and 52, respectively. PASI-90 was achieved in 27.8%, 62%, 64.6%, and 63.2% of patients at weeks 4, 12, 24, and 52, respectively; PASI-75 and PASI-90 responders were significantly more common among patients with a body mass index <30 kg/cm(2) and patients without previous biologic therapy failures. LIMITATIONS: Observational study. Time from onset of psoriasis was not evaluated. CONCLUSION: Secukinumab is a safe treatment with effectiveness rates similar to those found in its phase 3 studies. These rates endure up to a year from start of treatment.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/3341
url https://fisabio.portalinvestigacion.com/publicaciones/3341
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MOSBY-ELSEVIER
publisher.none.fl_str_mv MOSBY-ELSEVIER
dc.source.none.fl_str_mv JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
ISSN: 01909622
ISSNe: 10976787
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422588397092864
score 15,81155

Similares en LA Referencia